KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $11.9 million.

  • Recursion Pharmaceuticals' Non-Current Debt fell 4196.98% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 million, marking a year-over-year decrease of 4196.98%. This contributed to the annual value of $19.0 million for FY2024, which is 162770.21% up from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Non-Current Debt stood at $11.9 million, which was down 4196.98% from $14.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Non-Current Debt ranged from a high of $22.9 million in Q2 2024 and a low of $536000.0 during Q4 2022
  • Over the past 5 years, Recursion Pharmaceuticals' median Non-Current Debt value was $1.2 million (recorded in 2023), while the average stood at $7.1 million.
  • In the last 5 years, Recursion Pharmaceuticals' Non-Current Debt crashed by 9445.42% in 2021 and then soared by 188450.22% in 2024.
  • Recursion Pharmaceuticals' Non-Current Debt (Quarter) stood at $633000.0 in 2021, then decreased by 15.32% to $536000.0 in 2022, then soared by 105.41% to $1.1 million in 2023, then soared by 1627.7% to $19.0 million in 2024, then plummeted by 37.43% to $11.9 million in 2025.
  • Its last three reported values are $11.9 million in Q3 2025, $14.2 million for Q2 2025, and $16.4 million during Q1 2025.